BACKGROUND
A novel coronavirus (later named SARS-CoV-2, with the resulting illness named COVID-19) emerged in late 2019, with WHO declaring a global health emergency on 30 January 2020. The epidemic has since spread to all populated continents, with a global pandemic declared on 11 March 2020.
Public health measures against the COVID-19 pandemic have varied widely in strategy and success around the world.Β Travel restrictions in particular are presenting major challenges in logistics and transport for donated haemopoietic progenitor cells.Β Meanwhile there remains no evidence that SARS-CoV-2 is transmissible via blood or HPCs from a healthy donor lacking symptoms of COVID-19.
REFERENCES
WHO:Β https://www.who.int/emergencies/diseases/novel-coronavirus-2019
EBMT: https://www.ebmt.org/covid-19-and-bmt
COVID-19 is presenting major logistical challenges in managing and assessing HPC donors and in collecting and transporting HPC products.Β WMDA has developed a publicly-available resource page atΒ https://share.wmda.info/x/Yj6OF.
Contents
- Condition
- Guidance at RECRUITMENT for adult volunteer donor (NA for maternal donor (cord blood donation))
- Guidance at CT/WORK-UP
- Individual at Risk
- Justification
- References
Condition
Atherosclerotic or thrombotic occlusion of the coronary vasculature.
Pseudonyms and other related conditions include:
Angina
Ischaemic heart disease (IHD)
Myocardial infarction (MI)
Heart attack
Guidance at RECRUITMENT for adult volunteer donor (NA for maternal donor (cord blood donation))
UNACCEPTABLE
Guidance at CT/WORK-UP
UNACCEPTABLE, PERMANENT DEFERRAL
Individual at Risk
Donor
Justification
Myocardial infarction and angina have been well-documented as complications of both bone marrow and mobilised stem cell collection. In donors with known coronary artery disease, both processes pose an unacceptable risk to donor.
References
Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94(1): 94-101.
Be the first to like this